The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
ObjectiveTo assess the efficacy and safety of transarterial Chemoembolization (TACE) combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma (HCC).Patients and MethodsThe data of patients with unresectable HCC administered a combination therapy with TACE and lenvatinib plus...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.783480/full |
| _version_ | 1819095891141722112 |
|---|---|
| author | Fei Cao Yi Yang Yi Yang Tongguo Si Jun Luo Hui Zeng Zhewei Zhang Duiping Feng Yi Chen Jiaping Zheng |
| author_facet | Fei Cao Yi Yang Yi Yang Tongguo Si Jun Luo Hui Zeng Zhewei Zhang Duiping Feng Yi Chen Jiaping Zheng |
| author_sort | Fei Cao |
| collection | DOAJ |
| description | ObjectiveTo assess the efficacy and safety of transarterial Chemoembolization (TACE) combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma (HCC).Patients and MethodsThe data of patients with unresectable HCC administered a combination therapy with TACE and lenvatinib plus sintilimab were retrospectively assessed. Patients received lenvatinib orally once daily 2 weeks before TACE, followed by sintilimab administration at 200 mg intravenously on day 1 of a 21-day therapeutic cycle after TACE. The primary endpoints were objective response rate (ORR) and duration of response (DOR) by the modified RECIST criteria.ResultsMedian duration of follow-up was 12.5 months (95%CI 9.1 to 14.8 months). ORR was 46.7% (28/60). Median DOR in confirmed responders was 10.0 months (95%CI 9.0-11.0 months). Median progression-free survival (PFS) was 13.3 months (95%CI 11.9-14.7 months). Median overall survival (OS) was 23.6 months (95%CI 22.2-25.0 months).ConclusionsTACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma. |
| first_indexed | 2024-12-21T23:50:30Z |
| format | Article |
| id | doaj.art-bb5ca4c196604f0196ac9da99a38fa3e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T23:50:30Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-bb5ca4c196604f0196ac9da99a38fa3e2022-12-21T18:45:58ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-12-011110.3389/fonc.2021.783480783480The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective StudyFei Cao0Yi Yang1Yi Yang2Tongguo Si3Jun Luo4Hui Zeng5Zhewei Zhang6Duiping Feng7Yi Chen8Jiaping Zheng9Department of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, ChinaDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaKey Laboratory of Gene Editing Screening and Research and Development (R&D) of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, ChinaDepartment of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, ChinaDepartment of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, ChinaDepartment of Interventional Radiology, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Interventional Radiology, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, ChinaObjectiveTo assess the efficacy and safety of transarterial Chemoembolization (TACE) combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma (HCC).Patients and MethodsThe data of patients with unresectable HCC administered a combination therapy with TACE and lenvatinib plus sintilimab were retrospectively assessed. Patients received lenvatinib orally once daily 2 weeks before TACE, followed by sintilimab administration at 200 mg intravenously on day 1 of a 21-day therapeutic cycle after TACE. The primary endpoints were objective response rate (ORR) and duration of response (DOR) by the modified RECIST criteria.ResultsMedian duration of follow-up was 12.5 months (95%CI 9.1 to 14.8 months). ORR was 46.7% (28/60). Median DOR in confirmed responders was 10.0 months (95%CI 9.0-11.0 months). Median progression-free survival (PFS) was 13.3 months (95%CI 11.9-14.7 months). Median overall survival (OS) was 23.6 months (95%CI 22.2-25.0 months).ConclusionsTACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma.https://www.frontiersin.org/articles/10.3389/fonc.2021.783480/fullhepatocellular carcinomatransarterial chemoembolizationtargeted therapyimmunotherapycomprehensive therapy |
| spellingShingle | Fei Cao Yi Yang Yi Yang Tongguo Si Jun Luo Hui Zeng Zhewei Zhang Duiping Feng Yi Chen Jiaping Zheng The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study Frontiers in Oncology hepatocellular carcinoma transarterial chemoembolization targeted therapy immunotherapy comprehensive therapy |
| title | The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study |
| title_full | The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study |
| title_fullStr | The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study |
| title_full_unstemmed | The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study |
| title_short | The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study |
| title_sort | efficacy of tace combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma a multicenter retrospective study |
| topic | hepatocellular carcinoma transarterial chemoembolization targeted therapy immunotherapy comprehensive therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.783480/full |
| work_keys_str_mv | AT feicao theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT yiyang theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT yiyang theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT tongguosi theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT junluo theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT huizeng theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT zheweizhang theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT duipingfeng theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT yichen theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT jiapingzheng theefficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT feicao efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT yiyang efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT yiyang efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT tongguosi efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT junluo efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT huizeng efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT zheweizhang efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT duipingfeng efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT yichen efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy AT jiapingzheng efficacyoftacecombinedwithlenvatinibplussintilimabinunresectablehepatocellularcarcinomaamulticenterretrospectivestudy |